Chang Christopher Y, Chabot Peter, Walz Christopher M
Fauquier Ear Nose & Throat Consultants, PLC, Warrenton, VA 20186, USA.
Ear Nose Throat J. 2009 May;88(5):E18.
We conducted a survey to determine the current practices of a subset of physicians in the United States who treat patients with adductor spasmodic dysphonia. Surveys were sent to 169 physicians listed in the National Spasmodic Dysphonia Association database, and responses were returned by 43 (25.4%). Almost all respondents (95.4%) indicated that they use botulinum toxin type A injections, either alone or in combination with other treatments, to treat adductor spasmodic dysphonia, and most (69.8%) inject the toxin under electromyographic guidance. However, there were wide variations in the amount of sterile saline used to reconstitute the toxin, the size of the initial dose, and the use of other treatment strategies.
我们开展了一项调查，以确定美国一部分治疗内收型痉挛性发音障碍患者的医生的当前治疗方法。调查问卷被发送给了国家痉挛性发音障碍协会数据库中列出的169名医生，43名医生（25.4%）回复了问卷。几乎所有受访者（95.4%）表示，他们使用A型肉毒杆菌毒素注射单独或联合其他治疗方法来治疗内收型痉挛性发音障碍，大多数（69.8%）在肌电图引导下注射毒素。然而，用于复溶毒素的无菌生理盐水用量、初始剂量大小以及其他治疗策略的使用存在很大差异。
